Bempedoic acid for the treatment of dyslipidemia
Cardiovascular disease (CVD) is the leading cause of death worldwide and one key factor associated with the increased CVD risk is dyslipidemia. Statin therapy remains the first-line treatment to manage dyslipidemia, yet many patients do not achieve optimal low-density lipoprotein-cholesterol (LDL-C)...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2020-08-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/bempedoic-acid-for-the-treatment-of-dyslipidemia |
id |
doaj-a52df432d823429e9797d1b9616daa2f |
---|---|
record_format |
Article |
spelling |
doaj-a52df432d823429e9797d1b9616daa2f2020-11-25T03:54:23ZengBioExcel Publishing LtdDrugs in Context1740-43981740-43982020-08-0191910.7573/dic.2020-6-5Bempedoic acid for the treatment of dyslipidemiaJoel C MarrsSarah L AndersonCardiovascular disease (CVD) is the leading cause of death worldwide and one key factor associated with the increased CVD risk is dyslipidemia. Statin therapy remains the first-line treatment to manage dyslipidemia, yet many patients do not achieve optimal low-density lipoprotein-cholesterol (LDL-C) levels even after taking moderate- or high-intensity statins; therefore, additional, non-statin therapy is often needed. Bempedoic acid is a prodrug that, once activated, decreases LDL-C levels by the inhibition of adenosine triphosphate citrate lyase in the liver. Five clinical trials have demonstrated the safety and efficacy of bempedoic acid and the bempedoic acid/ezetimibe combination in lowering LDL-C in patients with atherosclerotic CVD and heterozygous familial hypercholesterolemia and also in high-risk primary prevention, and statin-intolerant patients. Bempedoic acid has been demonstrated to lower LDL-C levels by 15–25% in clinical trials and up to 38% when combined with ezetimibe. In 2020, the FDA approved bempedoic acid. Furthermore, the combination of bempedoic acid with ezetimibe is FDA approved for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic CVD who require additional LDL-C lowering after maximally tolerated statin therapy. The ongoing CLEAR OUTCOMES trial aims to evaluate whether bempedoic acid can reduce cardiovascular events in patients with statin intolerance and results will be available in the next 3 years. This outcomes trial will be pivotal for determining the role of bempedoic acid in the non-statin lipid-lowering armamentarium.https://www.drugsincontext.com/bempedoic-acid-for-the-treatment-of-dyslipidemiabempedoic acidcardiovascular eventsdyslipidemiahypercholesterolemialow-density lipoprotein-cholesterol |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joel C Marrs Sarah L Anderson |
spellingShingle |
Joel C Marrs Sarah L Anderson Bempedoic acid for the treatment of dyslipidemia Drugs in Context bempedoic acid cardiovascular events dyslipidemia hypercholesterolemia low-density lipoprotein-cholesterol |
author_facet |
Joel C Marrs Sarah L Anderson |
author_sort |
Joel C Marrs |
title |
Bempedoic acid for the treatment of dyslipidemia |
title_short |
Bempedoic acid for the treatment of dyslipidemia |
title_full |
Bempedoic acid for the treatment of dyslipidemia |
title_fullStr |
Bempedoic acid for the treatment of dyslipidemia |
title_full_unstemmed |
Bempedoic acid for the treatment of dyslipidemia |
title_sort |
bempedoic acid for the treatment of dyslipidemia |
publisher |
BioExcel Publishing Ltd |
series |
Drugs in Context |
issn |
1740-4398 1740-4398 |
publishDate |
2020-08-01 |
description |
Cardiovascular disease (CVD) is the leading cause of death worldwide and one key factor associated with the increased CVD risk is dyslipidemia. Statin therapy remains the first-line treatment to manage dyslipidemia, yet many patients do not achieve optimal low-density lipoprotein-cholesterol (LDL-C) levels even after taking moderate- or high-intensity statins; therefore, additional, non-statin therapy is often needed. Bempedoic acid is a prodrug that, once activated, decreases LDL-C levels by the inhibition of adenosine triphosphate citrate lyase in the liver. Five clinical trials have demonstrated the safety and efficacy of bempedoic acid and the bempedoic acid/ezetimibe combination in lowering LDL-C in patients with atherosclerotic CVD and heterozygous familial hypercholesterolemia and also in high-risk primary prevention, and statin-intolerant patients. Bempedoic acid has been demonstrated to lower LDL-C levels by 15–25% in clinical trials and up to 38% when combined with ezetimibe. In 2020, the FDA approved bempedoic acid. Furthermore, the combination of bempedoic acid with ezetimibe is FDA approved for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic CVD who require additional LDL-C lowering after maximally tolerated statin therapy. The ongoing CLEAR OUTCOMES trial aims to evaluate whether bempedoic acid can reduce cardiovascular events in patients with statin intolerance and results will be available in the next 3 years. This outcomes trial will be pivotal for determining the role of bempedoic acid in the non-statin lipid-lowering armamentarium. |
topic |
bempedoic acid cardiovascular events dyslipidemia hypercholesterolemia low-density lipoprotein-cholesterol |
url |
https://www.drugsincontext.com/bempedoic-acid-for-the-treatment-of-dyslipidemia |
work_keys_str_mv |
AT joelcmarrs bempedoicacidforthetreatmentofdyslipidemia AT sarahlanderson bempedoicacidforthetreatmentofdyslipidemia |
_version_ |
1724473982537695232 |